Topical immunotherapy treatment of alopecia areata with diphenylcyclopropenone: Regulatory T cells as biomarkers for treatment response.
alopecia areata
contact immunotherapy
dermoscopy
diphenylcyclopropenone
regulatory T cells
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
05
04
2022
received:
31
10
2021
accepted:
08
04
2022
pubmed:
19
4
2022
medline:
15
7
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
Treatment of alopecia areata is often challenging, especially for patients with extended disease. Contact immunotherapy with diphenylcyclopropenone (DPCP) has been reported as an effective topical treatment but the exact immunologic mechanism of diverting the immune response is still unknown. We investigated the efficacy of topical immunotherapy with DPCD in acute, intermediate, and chronic lesions of AA and the response rate was associated with perifollicular infiltrate of T regulatory cells. Approximately two-thirds of our patients (67.5%) had a response rate > 50% after 6 months of DPCP therapy. Patients with acute and intermediate onset of the disease were more likely to respond to the therapy. Although responders demonstrated FOXP3+ positive lymphocytes in immunohistochemistry, this association could not be confirmed by statistical significance (p = 0.052). In patients with multiple lesions, that had different chronological onset, the lesions with more recent onset responded faster than lesions of longer duration.
Substances chimiques
Biomarkers
0
Cyclopropanes
0
Immunologic Factors
0
diphenylcyclopropenone
I7G14NW5EC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15522Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Bröcker E-B, Echternacht-Happle K, Hamm H, Happle R. Abnormal expression of class I and class II major histocompatibility antigens in alopecia Areata: modulation by topical immunotherapy. J Invest Dermatol. 1987;88(5):564-568. doi:10.1111/1523-1747.ep12470166
Giordano CN, Sinha AA. Cytokine pathways and interactions in alopecia areata. Eur J Dermatol. 2013;23(3):308-318. doi:10.1684/ejd.2013.2042
Dy LC, Whiting DA. Histopathology of alopecia areata, acute and chronic: why is it important to the clinician?Dermatol Ther. 2011;24(3):369-374. doi:10.1111/j.1529-8019.2011.01414.x
Buckley DA, Du Vivier AWP. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol. 2008;145(3):385-405. doi:10.1111/j.1365-2133.2001.04399.x
Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39(5):751-761. doi:10.1016/s0190-9622(98)70048-9
Nasimi M, Abedini R, Ghandi N, Seirafi H, Mehdizade MS, Tootoonchi N. Topical immunotherapy with diphenylcyclopropenone in patients with alopecia areata: a large retrospective study of 757 patients. Dermatol Ther. 2020;33(6):e13808. doi:10.1111/dth.13808
Yoshimasu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev. 2016;15(7):664-667. doi:10.1016/j.autrev.2016.02.021
Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44(1):73-76. doi:10.1067/mjd.2001.109309
Avgerinou G, Gregoriou S, Rigopoulos D, Stratigos A, Kalogeromitros D, Katsambas A. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol. 2008;22(3):320-323. doi:10.1111/j.1468-3083.2007.02411.x
Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol. 2007;32(1):48-51. doi:10.1111/j.1365-2230.2006.02256.x
Lee S, Kim BJ, Lee YB, Lee W-S. Hair regrowth outcomes of contact immunotherapy for patients with alopecia Areata. JAMA Dermatol. 2018;154(10):1145. doi:10.1001/jamadermatol.2018.2312
Shapiro J, Otberg N. Alopecia areata: pathogenesis, clinical features, diagnosis, and management. Hair loss and restoration. CRC Press; 2015:85-146.
Gupta AK, Carviel J, Abramovits W. Treating alopecia Areata: current practices versus new directions. Am J Clin Dermatol. 2016;18(1):67-75. doi:10.1007/s40257-016-0230-4
Abedini R, Alipour E, Ghandi N, Nasimi M. Utility of Dermoscopic evaluation in predicting clinical response to Diphencyprone in a cohort of patients with alopecia Areata. Int J Trichology. 2020;12(3):107-113. doi:10.4103/ijt.ijt_73_20
Paus R, Bulfone-Paus S, Bertolini M. Hair follicle immune privilege revisited: the key to alopecia Areata management. J Investig Dermatol Symp Proc. 2018;19(1):S12-S17. doi:10.1016/j.jisp.2017.10.014